Research and treatment (2021) 188:117-131 clinical trial eribulin‑based for triple‑negative patients stratified by status: multicenter randomized phase ii clinical trial

HIGHLIGHTS

• who: BRCA​mutation status Eribulin Homologous et al. from the usefulness of patient stratification using HRD have published the research work: Research and Treatment (2021) 188:117-131 CLINICAL TRIAL Eribulin‑based for triple‑negative patients stratified by status: multicenter randomized phase II clinical trial, in the Journal: (JOURNAL)
• what: One of the aims of this study was to use response predictors to identify patients most likely to benefit from chemotherapy. The authors evaluated their usefulness as response predictors in TNBC patients receiving carboplatin in combination with standard paclitaxel- or eribulin-based regimens, for the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.